for people ages 40 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion



The purpose of this study is to assess the long-term safety and efficacy of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP). In a subset of participants at participating sites, participants will be assigned digital sensor BioStamp to assess body position and gait.


Progressive Supranuclear Palsy (PSP) tauopathy Steele-Richardson-Olszewski Syndrome PSP Supranuclear Palsy, Progressive ABBV-8E12


You can join if…

Open to people ages 40 years and up

  • Subject completed the 52-week treatment period in Study M15-562 (NCT02985879).
  • In the opinion of the investigator, the subject was compliant during participation in Study M15-562 (NCT02985879).
  • Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend).

You CAN'T join if...

  • Subjects who weigh less than 44 kg (97 lbs) at the time of study entry.
  • Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI).
  • Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results.
  • More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-562 (NCT02985879).
  • Subject is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the subject is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations.


  • Univ California, San Francisco /ID# 165553
    San Francisco California 94143-2204 United States
  • Cedars-Sinai Medical Center /ID# 165567
    Beverly Hills California 90211 United States


accepting new patients by invitation only
Start Date
Completion Date
Phase 2
Study Type
Last Updated